Arrowhead Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 59.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.46B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...